Filing identity and reporting period
Important identity discrepancy: The supplied filing is Cactus Ventures, Inc.’s Form 10-Q for the quarter ended September 30, 2011—not an Actinium Pharmaceuticals filing. Cactus describes itself as an inactive shell seeking a merger. The financial statements report results for the nine months ended September 30, 2011 and 2010; the filing does not provide a clear third-quarter income statement in the supplied text.
Financial results and condition
- Revenue: No operating revenue in either nine-month period.
- Profit: Reported net income was $12,936 in 2011, versus $10,196 in 2010. Results depended on non-operating gains from retained deposits: $25,000 and $35,000, respectively. Operating losses were $8,471 and $18,818.
- Expenses and interest: Total expenses declined to $8,471 from $18,818; interest expense declined to $3,593 from $5,152. The filing says expenses were general and administrative, primarily professional, legal, and accounting fees.
- Cash flow: Operating cash flow was $4,955, compared with $12,910 in 2010. Investing activities used $25,000 to retire a note; financing activities provided $20,045. Cash remained $150, unchanged from year-end 2010.
- Liquidity and debt: Assets consisted of $150 cash. Total liabilities were $81,832, including $53,753 in related-party notes payable, $24,839 in accrued interest, $1,740 in accrued legal fees, and $1,500 in accounts payable. Working capital deficiency was $27,929; shareholders’ deficit was $81,682.
- Margins and other metrics: Gross profit and operating margins are not meaningful because there was no revenue. The filing reports loss per share of $0.01 despite positive net income, an apparent inconsistency requiring verification. Weighted-average shares were 11,155,008.
Changes versus the prior comparable period
Operating expenses and interest expense were lower than in the first nine months of 2010, while reported net income increased. However, the deposit-retention gain was also lower, and reported income in both periods depended on that gain rather than operating activity. Cash stayed at $150, while total liabilities declined from $94,768 at December 31, 2010 to $81,832 at September 30, 2011.
Outlook, risks, and unusual items
- Management planned to continue searching for a business acquisition and estimated expenses of approximately $20,000 over the next 12 months. It expected advances from the president to fund operations but gave no assurance those advances would be available.
- The filing states that substantial doubt exists about the company’s ability to continue as a going concern, citing its working-capital and shareholders’ deficits and dependence on additional funding.
- A nonbinding letter of intent signed in April 2011 contemplated a share exchange with a private company; its closing date was amended to no later than July 31, 2011. The supplied filing does not clearly state the outcome. Elsewhere, management says it has no current acquisition understandings, commitments, or agreements.
- Any business combination could require a significant share issuance and dilute existing shareholders. The company also warns that it may be unable to identify or complete a suitable transaction, raise capital, or manage an acquired business successfully.
- The filing reports no legal proceedings, unregistered equity sales, defaults upon senior securities, or changes in internal control that materially affected financial reporting.
Investor verification priorities
- Confirm the issuer: the supplied document identifies Cactus Ventures, Inc., not Actinium Pharmaceuticals.
- Verify the reported positive net income against the stated loss-per-share figure and the filing’s inconsistent presentation of quarterly-period data.
- Determine the status and any subsequent outcome of the 2011 letter of intent and the $25,000 deposit.
- Assess the availability, terms, and related-party nature of funding needed to meet near-term expenses and address going-concern uncertainty.
- Review potential dilution and the terms of any merger or share-exchange transaction.